Paion Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 7/20/2025)
| Balance Sheet | Total Assets | 52,000,000.00 | ROE | – |
| Balance Sheet | Total Equity | -21,000,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -1,000,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -8,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | -7,000,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.63 | Div. Yield | – |
| Income | Net Income | -8,000,000.00 | P/E | – |
| Income | Shares Outstanding | 72,727,300.00 | P/B | – |
| Income | Total Revenue | 27,600,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.paion.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more